David A. Horwitz, Founder

Founder
General Nanotherapeutics, LLC

Poster(s):

• Th145 - Tolerogenic IL-2 Containing Nanoparticles Induce CD4 and CD8 Regulatory T Cells and TGF-β Producing Regulatory NK Cells That Provide Essential Support for the Tregs Which Suppress Immune-Mediated Disorders
  Thursday, June 20, 2024

  7:30 AM – 7:45 PM PT